X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ALEMBIC PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ALEMBIC PHARMA CADILA HEALTHCARE/
ALEMBIC PHARMA
 
P/E (TTM) x 17.9 21.9 81.8% View Chart
P/BV x 4.1 5.2 78.6% View Chart
Dividend Yield % 1.0 0.7 153.4%  

Financials

 CADILA HEALTHCARE   ALEMBIC PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ALEMBIC PHARMA
Mar-18
CADILA HEALTHCARE/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs558645 86.5%   
Low Rs362470 76.9%   
Sales per share (Unadj.) Rs116.3166.1 70.0%  
Earnings per share (Unadj.) Rs17.921.9 81.6%  
Cash flow per share (Unadj.) Rs23.127.5 84.1%  
Dividends per share (Unadj.) Rs3.504.00 87.5%  
Dividend yield (eoy) %0.80.7 106.1%  
Book value per share (Unadj.) Rs85.4117.8 72.5%  
Shares outstanding (eoy) m1,023.74188.52 543.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.4 117.8%   
Avg P/E ratio x25.725.5 101.1%  
P/CF ratio (eoy) x19.920.3 98.0%  
Price / Book Value ratio x5.44.7 113.7%  
Dividend payout %19.618.3 107.2%   
Avg Mkt Cap Rs m470,664105,090 447.9%   
No. of employees `00011.8NA-   
Total wages/salary Rs m18,5456,228 297.8%   
Avg. sales/employee Rs Th10,072.7NM-  
Avg. wages/employee Rs Th1,569.1NM-  
Avg. net profit/employee Rs Th1,547.7NM-  
INCOME DATA
Net Sales Rs m119,04931,308 380.2%  
Other income Rs m1,13270 1,610.2%   
Total revenues Rs m120,18131,378 383.0%   
Gross profit Rs m28,4756,431 442.8%  
Depreciation Rs m5,3881,055 510.9%   
Interest Rs m91134 2,679.4%   
Profit before tax Rs m23,3085,413 430.6%   
Minority Interest Rs m6280-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,204 469.0%   
Profit after tax Rs m18,2924,128 443.1%  
Gross profit margin %23.920.5 116.4%  
Effective tax rate %24.222.2 108.9%   
Net profit margin %15.413.2 116.5%  
BALANCE SHEET DATA
Current assets Rs m82,00518,247 449.4%   
Current liabilities Rs m60,72011,235 540.5%   
Net working cap to sales %17.922.4 79.8%  
Current ratio x1.41.6 83.2%  
Inventory Days Days7386 85.5%  
Debtors Days Days9861 160.2%  
Net fixed assets Rs m83,70320,035 417.8%   
Share capital Rs m1,024377 271.6%   
"Free" reserves Rs m86,42121,824 396.0%   
Net worth Rs m87,44522,201 393.9%   
Long term debt Rs m25,5515,000 511.0%   
Total assets Rs m180,65339,411 458.4%  
Interest coverage x26.6160.2 16.6%   
Debt to equity ratio x0.30.2 129.7%  
Sales to assets ratio x0.70.8 83.0%   
Return on assets %10.610.6 100.6%  
Return on equity %20.918.6 112.5%  
Return on capital %22.019.7 111.5%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m42,68314,722 289.9%   
Fx outflow Rs m11,2427,026 160.0%   
Net fx Rs m31,4417,696 408.5%   
CASH FLOW
From Operations Rs m9,1933,124 294.3%  
From Investments Rs m-9,737-8,844 110.1%  
From Financial Activity Rs m5155,026 10.2%  
Net Cashflow Rs m-29-693 4.2%  

Share Holding

Indian Promoters % 74.8 74.1 100.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 2.9 286.2%  
FIIs % 5.9 9.1 64.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 13.9 79.1%  
Shareholders   44,069 49,328 89.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Dec 14, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS